![PDF) Active immunoprophyilaxis with uromune® decreases the recurrence of urinary tract infections at three and six months after treatment without relevant secondary effects PDF) Active immunoprophyilaxis with uromune® decreases the recurrence of urinary tract infections at three and six months after treatment without relevant secondary effects](https://i1.rgstatic.net/publication/336866750_Active_immunoprophyilaxis_with_uromuneR_decreases_the_recurrence_of_urinary_tract_infections_at_three_and_six_months_after_treatment_without_relevant_secondary_effects/links/5fc2529b92851c933f6b830f/largepreview.png)
PDF) Active immunoprophyilaxis with uromune® decreases the recurrence of urinary tract infections at three and six months after treatment without relevant secondary effects
UROMUNE® I: VALORACIÓN DE LOS BENEFICIOS DE LA INMUNOPROFILAXIS EN INFECCIONES DEL TRACTO URINARIO RECURRENTES DESDE LA FARMA
![Frontiers | Comparison of sublingual therapeutic vaccine with antibiotics for the prophylaxis of recurrent urinary tract infections Frontiers | Comparison of sublingual therapeutic vaccine with antibiotics for the prophylaxis of recurrent urinary tract infections](https://www.frontiersin.org/files/Articles/139735/fcimb-05-00050-HTML/image_m/fcimb-05-00050-t002.jpg)
Frontiers | Comparison of sublingual therapeutic vaccine with antibiotics for the prophylaxis of recurrent urinary tract infections
![Laboratorio Carnot Fortalece su Liderazgo en Inmunoterapia, con el Lanzamiento de MV 130 Bacmune y MV 140 Uromune - Ultimas Noticias México Laboratorio Carnot Fortalece su Liderazgo en Inmunoterapia, con el Lanzamiento de MV 130 Bacmune y MV 140 Uromune - Ultimas Noticias México](https://ultimasnoticiasmexico.com/wp-content/uploads/2022/08/WhatsApp-Image-2022-08-14-at-3.59.34-PM.jpeg)
Laboratorio Carnot Fortalece su Liderazgo en Inmunoterapia, con el Lanzamiento de MV 130 Bacmune y MV 140 Uromune - Ultimas Noticias México
![Active immunoprophyilaxis with uromune® decreases the recurrence of urinary tract infections at three and six months after treatment without relevant secondary effects | BMC Infectious Diseases | Full Text Active immunoprophyilaxis with uromune® decreases the recurrence of urinary tract infections at three and six months after treatment without relevant secondary effects | BMC Infectious Diseases | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12879-019-4541-y/MediaObjects/12879_2019_4541_Fig3_HTML.png)
Active immunoprophyilaxis with uromune® decreases the recurrence of urinary tract infections at three and six months after treatment without relevant secondary effects | BMC Infectious Diseases | Full Text
![Frontiers | Comparison of sublingual therapeutic vaccine with antibiotics for the prophylaxis of recurrent urinary tract infections Frontiers | Comparison of sublingual therapeutic vaccine with antibiotics for the prophylaxis of recurrent urinary tract infections](https://www.frontiersin.org/files/Articles/139735/fcimb-05-00050-HTML/image_m/fcimb-05-00050-t001.jpg)